Revlimid's 'three-fold' cancer risk added to US label
This article was originally published in Scrip
Executive Summary
The US FDA has posted a warning on its website highlighting data that demonstrate certain cancer patients treated with Celgene's Revlimid (lenalidomide) have an increased risk of developing new types of cancers. It has also updated Revlimid's label with the information.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.